NASDAQ:ADMP Adamis Pharmaceuticals - ADMP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.20 +0.01 (+2.77%) (As of 01/31/2023 05:32 PM ET) Add Compare Share Share Today's Range$0.19▼$0.2350-Day Range$0.14▼$0.2252-Week Range$0.12▼$0.73Volume927,011 shsAverage Volume529,106 shsMarket Capitalization$30.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Adamis Pharmaceuticals (NASDAQ:ADMP) StockAdamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.Read More Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMP Stock News HeadlinesJanuary 31, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)January 30, 2023 | americanbankingnews.comAdamis Pharmaceuticals Co. (NASDAQ:ADMP) Short Interest UpdateJanuary 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 23, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Now Covered by StockNews.comJanuary 22, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Stock Crosses Below 200-Day Moving Average of $0.26December 29, 2022 | finance.yahoo.comAdamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 15, 2022 | seekingalpha.comAdamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call TranscriptJanuary 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.November 15, 2022 | finance.yahoo.comAdamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 12, 2022 | msn.comA Preview Of Adamis Pharmaceuticals's EarningsNovember 7, 2022 | finance.yahoo.comAdamis Pharmaceuticals Schedules Third Quarter 2022 Financial Results Conference Call and Corporate UpdateOctober 18, 2022 | msn.comWhy fuboTV Shares Are Trading Higher By 11%; Here Are 22 Stocks Moving PremarketOctober 12, 2022 | msn.comWhy Cango Shares Are Trading Higher; Here Are 27 Stocks Moving PremarketOctober 5, 2022 | marketwatch.comAdamis Pharmaceuticals Shares Jump 14% On Potential Sale, Strategic AlternativesOctober 3, 2022 | nasdaq.comAdamis Pharma To Explore Strategic Alternatives; Stock Up 10%October 3, 2022 | finance.yahoo.comAdamis Announces Review of Strategic AlternativesSeptember 30, 2022 | seekingalpha.comAdamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic FailureSeptember 23, 2022 | seekingalpha.comADMP Adamis Pharmaceuticals CorporationSeptember 21, 2022 | seekingalpha.comAdamis says Phase 2/3 trial for COVID-19 therapy did not reach main goalSeptember 21, 2022 | marketwatch.comAdamis Pharmaceuticals Sink to New Lows After Study Failure >ADMPSeptember 21, 2022 | finance.yahoo.comAdamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No EfficacySeptember 21, 2022 | marketwatch.comAdamis Ends Tempol Covid-19 Study After Main Endpoint Missed >ADMPSeptember 21, 2022 | finance.yahoo.comAdamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk SubjectsSeptember 12, 2022 | finance.yahoo.comAdamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk SubjectsAugust 30, 2022 | thestreet.comAdamis Pharmaceuticals CorporationAugust 12, 2022 | finance.yahoo.comAdamis Pharmaceuticals Announces Results of Annual Meeting of StockholdersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMP Company Calendar Last Earnings11/14/2022Today1/31/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMP CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone(858) 997-2400FaxN/AEmployees116Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,830,000.00 Net MarginsN/A Pretax Margin-2,069.43% Return on Equity-237.90% Return on Assets-124.57% Debt Debt-to-Equity RatioN/A Current Ratio1.14 Quick Ratio1.01 Sales & Book Value Annual Sales$2.21 million Price / Sales13.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book1.18Miscellaneous Outstanding Shares149,980,000Free Float141,134,000Market Cap$30.07 million OptionableOptionable Beta1.22 Key ExecutivesDavid J. MarguglioPresident, Chief Executive Officer & DirectorDavid C. BenedictoChief Financial & Accounting OfficerThomas H. MollVice President-ResearchKey CompetitorsMagenta TherapeuticsNASDAQ:MGTAAeglea BioTherapeuticsNASDAQ:AGLELumos PharmaNASDAQ:LUMONovanNASDAQ:NOVNGeoVax LabsNASDAQ:GOVXView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 1,700 shares on 11/4/2022Ownership: 0.000%David J MarguglioSold 11,859 sharesTotal: $7,115.40 ($0.60/share)Dennis J Phd CarloSold 10,490 sharesTotal: $6,294.00 ($0.60/share)Ronald B MossSold 8,199 sharesTotal: $4,919.40 ($0.60/share)David C BenedictoSold 3,603 sharesTotal: $2,197.83 ($0.61/share)View All Insider TransactionsView All Institutional Transactions ADMP Stock - Frequently Asked Questions How have ADMP shares performed in 2023? Adamis Pharmaceuticals' stock was trading at $0.1693 at the beginning of 2023. Since then, ADMP stock has increased by 15.2% and is now trading at $0.1951. View the best growth stocks for 2023 here. Are investors shorting Adamis Pharmaceuticals? Adamis Pharmaceuticals saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 1,910,000 shares, a decrease of 23.9% from the December 31st total of 2,510,000 shares. Based on an average daily trading volume, of 754,700 shares, the short-interest ratio is presently 2.5 days. View Adamis Pharmaceuticals' Short Interest. When is Adamis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our ADMP earnings forecast. How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Co. (NASDAQ:ADMP) posted its earnings results on Monday, November, 14th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.51 million during the quarter. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK). What is Adamis Pharmaceuticals' stock symbol? Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP." Who are Adamis Pharmaceuticals' major shareholders? Adamis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss. View institutional ownership trends. How do I buy shares of Adamis Pharmaceuticals? Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adamis Pharmaceuticals' stock price today? One share of ADMP stock can currently be purchased for approximately $0.20. How much money does Adamis Pharmaceuticals make? Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $29.26 million and generates $2.21 million in revenue each year. How many employees does Adamis Pharmaceuticals have? The company employs 116 workers across the globe. How can I contact Adamis Pharmaceuticals? Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com. This page (NASDAQ:ADMP) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.